648904-28-3
648904-28-3 structure
- Name: Bavituximab
- Chemical Name: Bavituximab
- CAS Number: 648904-28-3
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2019-01-15 09:58:39
- Modify Date: 2024-01-05 12:16:54
-
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].
| Name | Bavituximab |
|---|
| Description | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
Phosphatidylserine (PS)[1] |
| In Vitro | Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1]. Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1]. Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2]. |
| In Vivo | Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2]. Animal Model: Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] Dosage: 100 μg/mouse (Bavituximab/β2GP1) Administration: Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) Result: Traced phosphatidylserine exposure in vivo in mice with tumors. |
| References |
| No Any Chemical & Physical Properties |